09.12.2009 • News

Solvay Q1 Operating Tops Forecast

Solvay posted a 53 % fall in recurring Q1 operating profit, beating estimates, but said full-year operating profit would be below 2008. Recurring earnings before interest and tax (REBIT) fell to €142 million. Last year, the company reported €300 million in Q1 REBIT. Solvay said the pharmaceuticals unit would achieve in 2009 a higher operating result than last year, but conditions remained difficult for chemicals and plastics and visibility was limited.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read